Fall Clinical Dermatology

Impact of Itch Sparks New Pipeline Direction
January 07, 2022

Skin sensitivity will be a factor in vehicles for new treatments.

What to Know: Phase 3 Findings on Promising Psoriasis Pipeline
October 24, 2021

Mark G. Lebwohl, MD, presents on what dermatologists need to know about the newest psoriasis studies during the Fall Clinical Dermatology Conference.

First Topical JAK Inhibitor Treats Whole-body AD
October 24, 2021

FDA approval of ruxolitinib (Opzelura, Incyte) adds the first new topical anti-inflammatory to the atopic dermatitis (AD) armamentarium in 50 years, but boxed warnings raise questions.

Botulinum Type A: Key Clinical Postulates
October 23, 2021

Botulinum type A injections are widely used across the dermatology and aesthetic medicine specialties. At the Fall Clinical Dermatology Conference 2021, Mark S Nestor, MD, PhD, highlights how to optimize the neurotoxin to improve patient care.

Acne in Skin of Color: It’s All About PIH
October 23, 2021

Racial disparities in antibiotic prescription also influence treatment decisions.

Step Up Skin Microbiome Understanding to Advance AD Treatment
October 23, 2021

People are born with sterile skin and then gain microbiota throughout their life. Lawrence J. Green, MD, FAAD, explains how this affects the skin barrier and ultimately plays a role in atopic dermatitis at the 2021 Fall Clinical Dermatology Conference.

GEP in Melanoma Detection with Darrell S. Rigel, MD, MS
October 22, 2021

In a video onsite at Fall Clinical Dermatology Conference, Darrell S. Rigel, MD, MS, highlights, in his own words, the potential of GEP as an adjunct to biopsy in melanoma detection.

COVID-19 Skin Symptoms in Children
October 22, 2021

Lawrence Eichenfield, MD, provides the newest updates in pediatric patient care, with a special update on COVID-19 skin symptoms in children.

Tralokinumab Meets Endpoints in Adolescent AD Trial
October 22, 2021

LEO Pharma releases the 16-week data regarding tralokinumab (Adtralza; LEO Pharma) as a treatment for adolescent patients aged 12 to 17 years.

If Approved, Cantharidin 0.7% Could be Standard of Molluscum Care
October 21, 2021

Cantharidin 0.7% could be an emerging standard for molluscum treatment.